| Aspen Group (APZ) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,298 |
Proposed issue of securities - APZ
|
29 Aug 2025 9:37AM |
$4.320 |
$5.700 |
risen by
31.94%
|
|
| Magnum Mining and Exploration Limited (MGU) ORDINARY FULLY PAID |
Materials |
$19 |
HIGH-GRADE RARE EARTH LEACH TESTING BEGINS
|
29 Aug 2025 9:37AM |
$0.007 |
$0.006 |
fallen by
14.29%
|
|
MGU - Price-sensitive ASX Announcement
Full Release
Key Points
- Leach testing of high-grade samples from Palmares REE Project has commenced.
- Palmares REE Project spans 18 tenements covering ~348km² in Bahia State, Brazil.
- Trench assays at Feirinha Prospect returned up to 1.69% TREO.
- Rock chip assays showed up to 1.31% TREO, enriched in Nd and Pr.
- G2 pegmatites are the main host rocks with consistent high-grade mineralization.
- 15 samples dispatched to ALS Laboratories for leach testing.
- Palmares is positioned within a region with district-scale potential for REE.
- Magnum is one of the largest landholders for REE in the region.
- Leach testing results expected by September end.
- Potential for Palmares as a significant REE project, pending testing results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$13 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.069 |
$0.040 |
fallen by
42.03%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 global sales revenue of A$7.3 million, up 49% from the prior year.
- North American Travelan® sales reached A$2.0 million, a 76% increase.
- Profit from hyperimmune products remained A$1.35 million.
- Increased selling and marketing investment by A$1.4 million.
- Focus on oral immunotherapeutics for gut-mediated diseases.
- Anticipates FDA Phase 2 meeting for Travelan® and IND approval for IMM-529 by end 2025.
- Australian launch of ProIBS planned for Q1 2026.
- Continued quarter-on-quarter growth of Travelan®.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$13 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.069 |
$0.040 |
fallen by
42.03%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 Global Sales Revenue was A$7.3 million, up 49% from the previous year.
- North American Travelan® sales increased by 76% to A$2.0 million.
- Profit from Hyperimmune products remained A$1.35 million, consistent with FY24.
- Increased investment in selling and marketing by A$1.4 million.
- Launch of ProIBS in Australia is scheduled for Q1 CY2026.
- Travelan® IMM-124E: Scheduled End of Phase 2 FDA meeting in 1H 2026.
- Anticipated FDA approval of IMM-529 (CDI) IND in December 2025.
- Immuron is a biopharmaceutical company focused on oral immunotherapeutics for gut mediated diseases.
- Cash & Term Deposit as of 30 June 2025 stood at A$5.9 million, excluding A$2.8 million raised from US placement in July 2025.
- Major shareholders include BNY Mellon Asset Management with 42.29% ownership.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$26 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.098 |
$0.090 |
fallen by
8.16%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue was $172.0 million, a 1% decrease from the prior period.
- EBITDA was reported at $12.0 million, in line with guidance.
- Normalised EBITDA increased by 4.8% to $19.5 million.
- Net Loss After Tax was $5.2 million compared to a minor loss last year.
- Revenue growth in Australia/New Zealand driven by Bunnings and grain storage.
- Revenue in developing markets increased by 14.4%.
- Challenges faced in the Americas due to tariffs and weak consumer confidence.
- Non-recurring costs included $5.4 million from D365 implementation and executive changes.
- Focus on market development and cost reduction, especially in the US and emerging markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$26 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.098 |
$0.090 |
fallen by
8.16%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue at $172 million, down 1% from prior year.
- EBITDA was $12 million, consistent with guidance.
- Net loss after tax was $5.2 million.
- Australian and New Zealand markets showed 7.6% revenue increase.
- Americas revenue declined by 11.3%, affected by tariffs and consumer sentiment.
- Developing markets like the Middle East, Europe, and Asia showed growth.
- Significant non-recurring costs impacted profitability.
- Plans to reset US operations and diversify manufacturing to reduce tariff impact.
- Expansion focus on the Middle East and Asia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$26 |
FY25 Results Announcement
|
29 Aug 2025 9:35AM |
$0.098 |
$0.090 |
fallen by
8.16%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- GALE Pacific Limited faced geopolitical and tariff challenges in FY25.
- Revenue decreased by 1.2% to $172 million.
- EBITDA declined by 15.5% to $12 million, with a net loss of $5.2 million.
- Americas revenue fell by 11.3%, impacted by consumer confidence and tariffs.
- Australia/New Zealand revenue grew 7.6% due to strong summer sales.
- Developing markets saw a 14.4% revenue increase from Middle East and Europe projects.
- Non-recurring costs totaled $5.4 million due to ERP and leadership transitions.
- FX expenses impacted profits by $2.1 million due to currency movements.
- Focus on streamlining U.S. operations and diversifying manufacturing for future growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$26 |
FY25 Results Announcement
|
29 Aug 2025 9:35AM |
$0.098 |
$0.090 |
fallen by
8.16%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- GALE Pacific faced geopolitical and tariff-related challenges in the US.
- Revenue decreased by 1.2% in FY25.
- Net loss after tax was reported at AUD 5.2 million.
- Revenue grew by 7.6% in Australia/New Zealand.
- Revenue increased by 14.4% in developing markets.
- GALE Pacific aims to restructure US operations and diversify manufacturing footprint in FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$30 |
Atomo Investor Webinar Presentation
|
29 Aug 2025 9:35AM |
$0.018 |
$0.037 |
risen by
105.56%
|
|
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
- |
Board changes to align with current scale
|
29 Aug 2025 9:35AM |
$0.056 |
$0.022 |
fallen by
60.71%
|
|
| Constellation Technologies Limited (CT1) ORDINARY FULLY PAID |
Information Technology |
$3 |
Appendix 4G
|
29 Aug 2025 9:35AM |
$0.002 |
$0.002 |
fallen by
0%
|
|
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$13 |
Appendix 4E Preliminary Final Report
|
29 Aug 2025 9:35AM |
$0.069 |
$0.040 |
fallen by
42.03%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- Comprehensive loss after tax of $5,253,209 for the year ended 30 June 2025.
- Revenue from contracts with customers increased to $7,287,002.
- Net assets decreased to $8,031,833 from $12,709,444 in the previous year.
- Significant decrease in cash and cash equivalents to $2,830,526.
- Share capital increased to $88,872,756 due to share issues.
- Continued issuance of options and performance rights to key personnel.
- Post-year-end capital raising through At The Market facility in July 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$13 |
Appendix 4E Preliminary Final Report
|
29 Aug 2025 9:35AM |
$0.069 |
$0.040 |
fallen by
42.03%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 48.6% to $7,287,002.
- Loss after tax reduced by 24.3% to $5,253,209.
- Research and development expenses of $3,597,296.
- Cash position decreased to $2,830,526.
- No dividends paid or declared for the current or previous financial year.
- Continued strong sales of Travelan® in Australia and North America.
- 23.6% interest in Ateria Health Limited.
- Detailed audited financial statements expected by 30 September 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flexiroam Limited (FRX) ORDINARY FULLY PAID |
Communication Services |
$33 |
Corporate Governance Statement and Appendix 4G
|
29 Aug 2025 9:34AM |
$0.006 |
$0.022 |
risen by
266.67%
|
|
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$26 |
FY 25 Appendix 4G and Corporate Governance Statement
|
29 Aug 2025 9:34AM |
$0.098 |
$0.090 |
fallen by
8.16%
|
|
| Finexia Financial Group Limited (FNX) ORDINARY FULLY PAID |
Financials |
$12 |
Suspension from Quotation
|
29 Aug 2025 9:34AM |
$0.145 |
$0.190 |
risen by
31.03%
|
|
FNX - Price-sensitive ASX Announcement
Full Release
Key Points
- The securities of Finexia Financial Group Limited will be suspended from quotation immediately.
- The suspension is under Listing Rule 17.3.4.
- Suspension is pending the release of an announcement related to media speculation and a potential material acquisition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$30 |
2025 Appendix 4G and Corporate Governance Statement
|
29 Aug 2025 9:34AM |
$0.018 |
$0.037 |
risen by
105.56%
|
|
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$26 |
FY25 Annual Report
|
29 Aug 2025 9:34AM |
$0.098 |
$0.090 |
fallen by
8.16%
|
|
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$30 |
FY25 Results Presentation
|
29 Aug 2025 9:34AM |
$0.018 |
$0.037 |
risen by
105.56%
|
|
| Constellation Technologies Limited (CT1) ORDINARY FULLY PAID |
Information Technology |
$3 |
2025 Corporate Governance Statement
|
29 Aug 2025 9:33AM |
$0.002 |
$0.002 |
fallen by
0%
|
|
| EPX Limited (EPX) ORDINARY FULLY PAID |
Information Technology |
$21 |
2025 Results Announcement
|
29 Aug 2025 9:32AM |
$0.029 |
$0.245 |
risen by
744.83%
|
|
EPX - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory revenue increased by 17% to $15.3 million.
- Recurring revenue grew by 23% to account for 98% of total revenue.
- Underlying EBITDA loss decreased by 56% to $0.6 million.
- Net loss after tax was $5.75 million.
- Operational cash flow was positive at $1.4 million.
- Expenses increased due to strategic investments and acquisition costs.
- EPX launched the EDGE Industrial platform.
- Focus on expanding into commercial, hotel, and retail office markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EPX Limited (EPX) ORDINARY FULLY PAID |
Information Technology |
$21 |
2025 Results Announcement
|
29 Aug 2025 9:32AM |
$0.029 |
$0.245 |
risen by
744.83%
|
|
EPX - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory revenue increased by 17% to $15.3 million.
- Recurring revenue grew by 23%, representing 98% of total revenue.
- Net loss after tax increased by 15% to $5.75 million.
- Underlying EBITDA loss reduced by 56% to $0.6 million.
- Significant operational cash inflow of $1.4 million.
- Acquisition of Coda Cloud technology and launch of Edge Industrial.
- Rebranding to 'epx'.
- Focus on growth in commercial, hotel, and retail office verticals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EPX Limited (EPX) ORDINARY FULLY PAID |
Information Technology |
$21 |
2025 Appendix 4G and Corporate Governance Statement
|
29 Aug 2025 9:32AM |
$0.029 |
$0.245 |
risen by
744.83%
|
|
| Golden Horse Minerals Limited (GHM) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$179 |
Management Discussion & Analysis June 2025
|
29 Aug 2025 9:31AM |
$0.475 |
$0.705 |
risen by
48.42%
|
|
| Caprice Resources Limited (CRS) ORDINARY FULLY PAID |
Materials |
$74 |
Application for quotation of securities - CRS
|
29 Aug 2025 9:31AM |
$0.088 |
$0.105 |
risen by
19.32%
|
|
Call 1300 880 160
Start a chat
Schedule a call
